🔬 Don't miss the latest Business of @MyBioTechniques!. This month, we highlight #drugdiscovery #technology partnerships, product launches to support #cellandgenetherapy process development, & #investment in early #disease detection & #precisionmedicine ➡

Today @Optibrium announced that it has secured a multi-million-pound financing package from Shawbrook. The funding will be used to support improvements of the Company’s core technologies, build technical capabilities and support further global expansion.

Today SolasCure announced the publication of a peer-reviewed study in the International Wound Journal. Building on positive Phase IIA clinical findings, the study reinforces Aurase Wound Gel's favourable safety profile and pain-free application. More:

.@BioRad today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The instruments include Bio-Rad’s QX Continuum™ and the QX700™ platforms acquired as part of the recent acquisition of digital PCR developer Stilla Technologies:

Today @Optibrium announced a partnership with TalTech to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme. The PhD research will focus on developing faster and more accurate methods for predicting drug metabolism. More:

4basebio introduces new branding to reflect the Company's next phase of growth on its mission to deliver scalable, high-quality synthetic DNA solutions to the global market. Read the full press release:

Today @ShiftBioscience announced the results of a new study detailing an improved approach to ranking virtual cell models for gene discovery. Read more:

📣 Today marks 15 years since Zyme was founded, and we're proud to have built a strong global life science network, driven by a dedicated team of passionate scientists & communications specialists. To celebrate, we’ve introduced a refreshed look! . ➡

Today Enhanced Genomics announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge to identify multiple novel therapeutic targets for Alzheimer’s disease using Enhanced’s 3D multi-omics platform. More:

OutSee raises £1.8M seed funding to expand and progress the Company's in-house target development program using its proprietary AI-based predictive genomics technology, Nomaly. Read more:

.@BioRad is expanding its portfolio of anti-idiotypic antibodies and SpyCatcher reagents—supporting robust, reliable bioanalytical assays and enabling therapeutic drug monitoring for innovator and biosimilar biologics. Read more:

Qureight today announced that its digitally-twinned synthetic control arm has been used in a breakthrough #clinicaltrial application in place of a human placebo group. The study demonstrates significant clinical efficacy for Avalyn’s inhaled pirfenidone:

.@SphereBioLtd has expanded its operations in China, selecting Redbert Biotechnology as its exclusive distribution partner and appointing Johnathan Fu as China Distribution Manager to lead regional partnerships and enhance customer support. More:

.@Mursla has introduced its AI Precision Medicine Platform. Through extracellular vesicle isolation from blood, the Platform enables differentiated AI-powered biomarker discovery. Published pre-print data demonstrates its capability in liver disease.

Today SolasCure announced that the FDA has granted Fast Track Designation for its investigational Aurase Wound Gel, in the treatment of patients with calciphylaxis ulcers, widening its application in the healing of chronic wounds. Read more:

.@KadansScience has completed construction of the primary structure of Merlin Place, Cambridge, a purpose-built laboratory facility designed to encourage collaboration and advance life sciences and health innovation. Read more:

This week, @tagomics has been awarded £860k @innovateuk funding as part of the Biomedical Catalyst grant for a £1.2M project to customise its multiomic profiling platform, Interlace, for the early detection of colorectal cancer. Read more:

Centauri Therapeutics has published a peer-reviewed study in the Journal of Immunology, presenting the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections. Read the full press release:

Enhanced Genomics today announced the appointment of Dietrich Stephan, Ph.D. as Chair to lead the management team in implementing the Company’s plans to drive expansion of its internal target identification pipeline and establish strategic partnerships ➡️

Today @CN_Bio introduced cross species DILI services to its Contract Research Services. Extending the capabilities of the Company’s PhysioMimix DILI assay, these services will enhance in vitro to in vivo extrapolation during preclinical drug development.

Today @ShiftBioscience announced the publication of new research identifying a novel single-gene target for cellular rejuvenation. SB000 reverses cellular aging across multiple cell types without inducing dangerous pluripotency pathways. Learn more➡️